BioSyent Inc. Stock

Equities

RX

CA0906901081

Pharmaceuticals

Market Closed - Toronto S.E. 03:52:05 2024-07-12 pm EDT 5-day change 1st Jan Change
10 CAD -0.40% Intraday chart for BioSyent Inc. 0.00% +8.46%
Sales 2024 * 35M 25.65M Sales 2025 * 38.7M 28.36M Capitalization 116M 84.95M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.31 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3 x
P/E ratio 2024 *
18.2 x
P/E ratio 2025 *
15.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 60.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.40%
1 month+5.15%
3 months+15.61%
6 months+16.28%
Current year+8.46%
More quotes
1 week
10.00
Extreme 10
10.23
1 month
9.21
Extreme 9.21
10.75
Current year
8.24
Extreme 8.24
10.75
1 year
7.41
Extreme 7.41
10.75
3 years
6.24
Extreme 6.24
10.75
5 years
3.13
Extreme 3.13
10.75
10 years
3.13
Extreme 3.13
12.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 95-12-31
Director of Finance/CFO - 18-09-09
Chief Tech/Sci/R&D Officer - 14-04-30
Members of the board TitleAgeSince
Director/Board Member 53 18-01-07
Chief Executive Officer 64 95-12-31
Director/Board Member 60 02-05-31
More insiders
Date Price Change Volume
24-07-12 10 -0.40% 4,105
24-07-11 10.04 +0.10% 1,493
24-07-10 10.03 -0.20% 1,205
24-07-09 10.05 +0.50% 4,100
24-07-08 10 0.00% 32,953

Delayed Quote Toronto S.E., July 12, 2024 at 03:52 pm EDT

More quotes
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
10 CAD
Average target price
9.65 CAD
Spread / Average Target
-3.50%
Consensus